Core Viewpoint - The article highlights the ongoing issue of false advertising in the sale of health products, particularly those claiming to treat uterine fibroids, and the inadequate regulatory response to these practices [1][20][22]. Group 1: Product Changes and Regulatory Response - Following the publication of a consumer quality report, several products claiming to treat uterine fibroids have been taken down or had their promotional content altered, yet many other products with misleading claims remain available [2][15]. - Specific products, such as the "Anpical Uterine Fibroids capsules," have had their claims modified to remove references to fibroids, while still being sold under different descriptions [3][8]. - The market regulation authorities have intensified efforts to combat false advertising, with significant penalties imposed on violators, including a total of 6,876.91 million yuan in fines since the start of the year [22]. Group 2: Expert Opinions and Recommendations - Experts emphasize the need for a robust credit punishment mechanism to deter businesses from engaging in false advertising, suggesting that violators should be included in a social credit system [1][20]. - There is a call for improved regulatory frameworks to better define and penalize false advertising, as well as for platforms to enhance their vetting processes for sellers [21][22]. - The article notes that consumer awareness and ability to identify false claims are crucial in combating misleading advertisements, with recommendations for consumers to retain evidence of promotional materials [20][21].

Core Viewpoint - The article highlights the rise of misleading products claiming to treat uterine fibroids, exploiting women's anxiety and fear of surgery, leading to potential health risks due to reliance on ineffective treatments [1][2][3]. Group 1: Misleading Products - A variety of products, including medical devices and herbal remedies, are marketed as capable of "eliminating" uterine fibroids, often using exaggerated claims and false advertising [1][25]. - Many of these products, particularly medical adhesive patches, falsely claim to contain traditional Chinese medicine ingredients, despite regulations prohibiting such claims for Class I medical devices [3][16][24]. - The marketing strategies often target the psychological fears of women regarding surgery, promoting the idea of "no surgery, no medication" as a selling point [1][24]. Group 2: Expert Opinions - Medical professionals emphasize that uterine fibroids are common and typically do not require immediate treatment unless they exceed 5 cm in size or cause symptoms [2][31]. - Experts assert that there is no scientific evidence supporting the claims that these products can shrink or eliminate fibroids, and reliance on them may delay necessary medical treatment [17][28][29]. - The use of herbal patches and foot baths is deemed ineffective for treating fibroids, with experts noting that while they may provide temporary relief from discomfort, they do not address the underlying condition [28][29]. Group 3: Regulatory Concerns - The article discusses the regulatory violations associated with these products, including misleading claims about their medical efficacy and improper labeling of medical device registration numbers [16][37]. - Some products have been found to have inconsistent or unverifiable medical device registration numbers, raising concerns about their legitimacy [37][40]. - The use of terms like "imported" or "Japanese technology" in marketing is identified as a tactic to mislead consumers about the product's origins and effectiveness [32][36].